Stage (next event)
Catalyst Info & Data Links
TITLE: RHB-102 (Bekinda®) in Gastroenteritis & gastritis
ClinicalTrial.gov (NCT02246439): BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (GUARD)
ClinicalTrial.gov (NCT02757105): Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
RHB-102 (Bekinda) is a proprietary, bimodal extended-release (24 hours) oral tablet formulation of, ondansetron, covered by several issued and pending patents. A positive first Phase 3 clinical study with RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis successfully met its primary endpoint. A positive Phase 2 study with RHB-102 (Bekinda) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), presented at the Digestive Diseases Week (DDW) meeting in 2018, also successfully met its primary endpoint.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post